Isaac Barchas Sells 15,248 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of Immunome stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $26.06, for a total value of $397,362.88. Following the sale, the director directly owned 72,416 shares in the company, valued at approximately $1,887,160.96. This trade represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Trading Up 2.2%

Shares of NASDAQ IMNM opened at $26.25 on Wednesday. The firm has a market capitalization of $2.97 billion, a price-to-earnings ratio of -11.03 and a beta of 2.08. Immunome, Inc. has a one year low of $8.66 and a one year high of $27.65. The business has a fifty day simple moving average of $21.73 and a 200 day simple moving average of $22.18.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, research analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on IMNM. Barclays began coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target for the company. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Truist Financial upped their price target on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Wedbush reissued an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Tuesday, July 21st. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.18.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP bought a new stake in Immunome during the second quarter worth about $25,000. E Fund Management Co. Ltd. bought a new position in shares of Immunome in the second quarter valued at approximately $248,000. Citizens Financial Group Inc. RI bought a new position in shares of Immunome in the second quarter valued at approximately $424,000. BlackRock Inc. bought a new position in shares of Immunome in the second quarter valued at approximately $186,588,000. Finally, Deutsche Bank AG acquired a new position in shares of Immunome in the 2nd quarter worth approximately $2,365,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.